New treatments for gout

Current Opinion in Investigational Drugs

Volumn 11, Issue 5, 2010, Pages 499-506

  Mapa, Janet B ^a   Pillinger, Michael H ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

Allopurinol; Allopurinol hypersensitivity syndrome; Caspase 1 inhibitor; Febuxostat; Gout; IL 1 inhibitor; Melanocyte stimulating hormone receptor agonist; Monosodium urate crystal; PEGylated uricase; URAT1 inhibitor

Indexed keywords

ADENURIC; ALLOPURINOL; ANTIGOUT AGENT; BENZBROMARONE; CANAKINUMAB; CAPTOPRIL; COLCHICINE; CYTOKINE; DIDANOSINE; FEBUXOSTAT; INTERLEUKIN 1BETA; OLURIC; PEGLOTICASE; PLACEBO; PROBENECID; RDEA 594; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; THEOPHYLLINE; THIOTEPA; UNCLASSIFIED DRUG; URATE; URATE OXIDASE; URIC ACID;

ANAPHYLAXIS; BONE MARROW DEPRESSION; CLINICAL TRIAL; COMORBIDITY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DRESS SYNDROME; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INFUSION REACTION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME REPLACEMENT; GASTROINTESTINAL DISEASE; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; IMMUNOGENICITY; INFLAMMATION; INJECTION SITE REACTION; KIDNEY FAILURE; LIVER FAILURE; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; NONHUMAN; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; STEVENS JOHNSON SYNDROME; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL;

ANIMALS; ARTHRITIS, GOUTY; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; GOUT; GOUT SUPPRESSANTS; HUMANS; TREATMENT OUTCOME;

EID: 77952171861     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Nuki G, Simkin P: A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther (2006) 8 (Suppl 1) : S1.
2. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, Gabriel S, Hirsch R, Hochberg MC, Hunder GG, Jordan JM, Katz JN, Kremers HM, Wolfe F, National Arthritis Data Workgroup: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum (2008) 59(1):26-35.
3. Kim KY, Schumacher HR, Hunsche E, Wertheimer A, Kong S: A literature review of the epidemiology and treatment of acute gout. Clinical Ther (2003) 25(6):1593-1617.
4. Campion EW, Glynn RJ, DeLabry LO: Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med (1987) 82(3):421-426.
5. Miao Z, Li C, Chen Y, Zhao S, Wang Y, Wang Z, Chen X, Xu F, Wang F, Sun R, Hu J et al: Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of eastern China. J Rheumatol (2008) 35(9):1859-1864.
6. Abramson SB: Treatment of gout and crystal arthropathies and uses and mechanisms of action of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol (1992) 4(3):295-300.
7. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW: High versus low dosing of oral colchicine for early acute gout fare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebocontrolled, parallel-group, dose-comparison colchicine study. Arthritis Rheum (2010) 62(4):1060-1068.
8. Abeles AM, Park JY, Pillinger MH, Cronstein BN: Update on gout: Pathophysiology and potential treatments. Curr Pain Headache Rep (2007) 11(6):440-446.
9. Tausche AK, Jansen TL, Schröder HE, Bornstein SR, Aringer M, Müller-Ladner U: Gout-Current diagnosis and treatment. Deutsches Ãrzteblatt Int (2009) 106 (34-35) : 549-555.
10. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, Hingorani A, Jaques R, Nuki G: British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (2007) 46(8):1372-1374.
11. Keith M, Gilliland W: Updates in the management of gout. Am J Med (2007) 120(3):221-224.
12. Burke A, Smyth E and FitzGerald GA: Analgesic-antipyretic agents; pharmacotherapy of gout. In: Goodman & Gilman's The Pharmacologic Basis of Therapeutics (11th Edition). Brunton LL, Lazo JS, Parker KL (Eds), McGraw-Hill Medical Professional, Maidenhead, UK (2006) : 671-716.
13. Stamp LK, O'Donnell JL, Chapman PT: Emerging therapies in the long-term management of hyperuricaemia and gout. Intern Med J (2007) 37(4):258-266.
14. Pillinger MH, Rosenthal P, Abeles AM: Hyperuricemia and gout: New insights into pathogenesis and treatment. Bull NYU Hosp Joint Dis (2007) 65(3):215-221.
15. Terkeltaub RA, Ginsberg MH: The inflammatory reaction to crystals. Rheum Dis Clin North Am (1988) 14(2):353-364.
16. Akahoshi T, Murakami Y, Kitasato H: Recent advances in crystal-induced acute inflammation. Curr Opin Rheumatol (2007) 19(2):146-150.
17. Chohan S, Becker MA: Update on emerging urate-lowering therapies. Curr Opin Rheumatol (2009) 21(2):143-149.
18. Dalbeth N, Haskard DO: Mechanisms of inflammation in gout. Rheumatology (2005) 44(9):1090-1096.
19. Choi HK, Mount DB, Reginato AM: Pathogenesis of gout. Ann Intern Med (2005) 143(7):499-516.
20. Duff G, Atkins E, SE M: The fever of gout: Urate crystals activate endogenous pyrogen production from human and rabbit mononuclear phagocytes. Trans Assoc Am Physicians (1983) 96:234-245.
21. Malawista SE, Duff GW, Atkins E, Cheung HS, McCarty DJ: Crystal-induced endogenous pyrogen production. A further look at gouty inflammation. Arthritis Rheum (1985) 28(9):1039-1046.
22. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature (2006) 440(7081):237-241.
23. Pétrilli V, Martinon F: The inflammasome, autoinflammatory diseases, and gout. Joint Bone Spine (2007) 74(6):571-576.
24. Liu-Bryan R, Scott P, Sydlaske A, Rose DM, Terkeltaub R: Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum (2005) 52(9):2936-2946.
25. Liu-Bryan R, Pritzker K, Firestein G, Terkeltaub R: TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J Immunol (2005) 174(8):5016-5023.
26. Ipsen: Menarini and Ipsen launch Adenuric for gout in the EU. Press Release (2010) : March 05.
27. Takeda Pharmaceutical Co Ltd: Uloric (febuxostat) 40-mg and 80-mg tablets now available for the chronic managementof hyperuricemia in patients with gout. Press Release (2009) : March 12.
28. Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T: An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem (2003) 278(3):1848-1855.
29. Bruce SP: Febuxostat: A selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother (2006) 40(12):2187-2194.
30. Uloric: Takeda Pharmaceuticals North America Inc, Deerfeld, IL, USA (2009). www.uloric.com/?gclid=CPmfJ6mjZwCFdVL5Qod9B umXw
31. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Eng J Med (2005) 353(23):2450-2461. • Important phase II, randomized, controlled trial comparing febuxostat and allopurinol, indicating that febuxostat was both efficacious and more effective than allopurinol in lowering plasma urate levels.
32. Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N: Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum (2008) 59(11):1540-1548. • Important phase III, randomized, controlled trial comparing febuxostat with allopurinol and placebo, indicating that febuxostat was both efficacious and more effective than allopurinol in reducing plasma urate levels in healthy individuals and in patients with mild-to-moderate renal insufficiency.
33. Application number NDA 21-856. Summary Review: US Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Bethesda, MD, USA (2009). www.accessdata.fda.gov/drugsatfda-docs/nda/2009/021856s000-SumRpdf
34. EPARs for authorised medicinal products for human use - Adenuric. Summary of product characteristics: European Medicines Agency (EMEA), London, UK (2008). www.ema. europa.eu/humandocs/Humans/EPAR/adenuric/adenuric.htm
35. Taylor WJ, Schumacher HR Jr, Singh JA, Grainger R, Dalbeth N: Assessment of outcome in clinical trials of gout - a review of current measures. Rheumatology (2007) 46(12):1751-1756.
36. Keenan RT, Pillinger MH: Febuxostat: A new agent for lowering serum urate. Drugs Today (2009) 45(4):247-260.
37. Royer R, Vindel J, Lamarche M, Kissel P: [Modalities of purine excretion during enzyme treatment of gout and other hyperuricemic conditions with urate oxidase]. Presse Méd (1968) 76(49):2325-2327.
38. Rampello E, Fricia T, Malaguarnera M: The management of tumor lysis syndrome. Nat Clin Pract Oncol (2006) 3(8):438-447.
39. Richette P, Bardin T: Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol. Nat Clin Pract Rheumatol (2006) 2(6):338-342.
40. Edwards NL: Treatment-failure gout: A moving target. Arthritis Rheum (2008) 58(9):2587-2590.
41. Baraf H, Kim S, AK M, AN M: Resolution of tophi with intravenous PEG-uricase in refractory gout. Arthritis Rheum (2005) 50 (Suppl 9) : S105.
42. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfeld MS: Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly (ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Ther (2006) 8 (1) : R12.
43. Sundy JS, Ganson NJ, Kelly SJ, Scarlett EL, Rehrig CD, Huang W, Hershfeld MS: Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum (2007) 56 (Suppl 3) : 1021-1028.
44. Sundy JS, Becker MA, Baraf HS, Barkhuizen A, Moreland LW, Huang W, Waltrip RW 2nd, Maroli AN, Horowitz Z: Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized study. Arthritis Rheum (2008) 58(9):2882-2891.
45. Sundy JS, Baraf HS, Becker MA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Horowitz Z: Efficacy and safety of intravenous (iv) pegloticase (PGL) in subjects with treatment failure gout (TFG) : Results from GOUT1 and GOUT2. Arthritis Rheum (2008) 58 (Suppl 9) : S400-S401. •• Key phase III, randomized, controlled trial comparing pegloticase versus placebo in patients with treatment-failure gout. Uratelowering in the pegloticase group was superior to the placebo group; an improvement in quality of life was also observed in the pegloticasetreated groups. In addition, pegloticase-treated patients developed anti-pegloticase antibodies, and almost all of these patients had some loss of pegloticase urate-lowering efficacy over time.
46. Baraf HS, Becker MA, Edwards NL, Gutierrez-Urena SR, Sundy JS, Treadwell EL: Tophus response to pegloticase (PGL) therapy: Pooled results of GOUT1 and GOUT2 PGL phase 3 randomized, doubleblind, placebocontrolled trials. Arthritis Rheum (2008) 58 (Suppl 9) : S176. •• Key phase III, randomized, controlled trial comparing pegloticase versus placebo in patients with treatment-failure gout. Pegloticase (8 mg) administered every 2 weeks resulted in complete resolution of tophi in 20% of patients in the first 13 weeks of treatment, and in 41% by the end of 6 months, compared with 7% of patients receiving placebo.
47. Straid V, Edwards NL, Baraf HS, Becker MA, Sundy JS, Huang JS, Forsythe B: Improvement in health-related quality of life (HRQL) and disability index in treatment failure gout (TFG) after pegloticase (PGL) therapy: Pooled results from GOUT1 and GOUT2, phase 3 randomized, double blind, placebo (PBO)-controlled trials. Arthritis Rheum (2008) 58 (Suppl 9) : S178. • Key phase III, randomized, controlled trial comparing pegloticase versus placebo in patients with treatment-failure gout. An improvement in quality of life was demonstrated in pegloticase-treated groups compared with the placebo group.
48. Becker MA, Treadwell EL, Baraf HS, Edwards NL, Gutierrez-Urena SR, Sundy JS, Horowitz Z: Immunoreactivity and clinical response to pegloticase (PGL) : Pooled data from GOUT1 and GOUT2, PGL phase 3, randomized: Double blind, placebo-controlled trials. Arthritis Rheum (2008) 58 (Suppl 9) : S880. • Important re-evaluation of phase III, randomized, controlled trial comparing pegloticase versus placebo in patients with treatmentfailure gout. This analysis highlighted that pegloticase-treated patients developed anti-pegloticase antibodies, and that almost all of these patients had some loss of pegloticase urate-lowering efficacy over time.
49. Summary Minutes of the Arthritis Advisory Committee: US Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Bethesda, MD, USA (2009). www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/ArthritisDrugsAdvisoryCommittee/UCM172499pdf
50. Savient Pharmaceuticals Inc: Savient pharmaceuticals receives complete response letter from US Food and Drug Administration for Krystexxa. Press Release (2009) : August 04.
51. So A, De Smedt T, Revaz S, Tschopp J: A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther (2007) 9 (2) : R28.
52. Terkeltaub R, Sundy JS, Schumacher HR, Murphy F, Bookbinder S, Biedermann S, Wu R, Mellis S, Radin A: The IL-1 inhibitor rilonacept in treatment of chronic gouty arthritis: Results of a placebo-controlled, monosequence crossover, nonrandomized, single-blind pilot study. Ann Rheum Dis (2009) 68(10):1613-1617.
53. So A, De Meulemeester M, Shamim T, Pikhlak A, Yücel AE, Arulmani U, Richard D, Murphy V, Sallstig P, Schlesinger N: Canakinumab (ACZ885) vs triamcinolone acetonide for treatment of acute fares and prevention of recurrent fares in gouty arthritis patients refractory to or contraindicated to NSAIDs and/or colchicine. American College of Rheumatology Scientific Meeting, Philadelphia, PA, USA (2009) : Abs L04.
54. Randle JC, Harding MW, Ku G, Schönharting M, Kurrle R: ICE/caspase-1 inhibitors as novel anti-inflammatory drugs. Expert Opin Investig Drugs (2001) 10(7):1207-1209.
55. Cornelis S, Kersse K, Festjens N, Lamkanf M, Vandenabeele P: Inflammatory caspases: Targets for novel therapies. Curr Pharm Des (2007) 13(4):367-385. (Pubitemid 46477759)
56. Getting SJ, Perretti M: Arthritic diseases: Melanocortin type 3 receptor agonists as potential therapeutics. Curr Opin Investig Drugs (2001) 2(8):1064-1069. (Pubitemid 32780705)
57. Getting SJ, Allcock GH, Flower R, Perretti M: Natural and synthetic agonists of the melanocortin receptor type 3 possess anti-inflammatory properties. J Leukoc Biol (2001) 69(1):98-104.
58. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, García-Erauskin G, Ruiz-Lucea E: Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis (1998) 57(9):545-549.
59. Heel RC, Brogden RN, Speight TM, Avery GS: Benzbromarone: A review of its pharmacological properties and therapeutic use in gout and hyperuricaemia. Drugs (1977) 14(5):349-366.
60. Reinders MK, van Roon EN, Houtman PM, Brouwers JR, Jansen TL: Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromaronetreated gout patients. Clin Rheumatol (2007) 26(9):1459-1465.
61. Hautekeete ML, Henrion J, Naegels S, DeNeve A, Adler M, Deprez C, Devis G, Klöppel G: Severe hepatotoxicity related to benzarone: A report of three cases with two fatalities. Liver (1995) 15(1):25-29.
62. Arai M, Yokosuka O, Fujiwara K, Kojima H, Kanda T, Hirasawa H, Saisho H: Fulminant hepatic failure associated with benzbromarone treatment: A case report. J Gastroenterol Hepatol (2002) 17(5):625-626.
63. Yeh L, Kerr B, Shen Z, Hingorari V, Sheedy B, Nguyen M, Polvent L, Manhard K, Quart B: Safety, pharmacokinetics, and serum uric acid lowering effect of RDEA594, a novel uricosuric agent, in healthy volunteers. Annual European Congress of Rheumatology, Copenhagen, Denmark (2009).
64. Investor Center: Ardea Biosciences Inc, San Diego, CA, USA (2009). investorcenter.ardeabio.com/phoenix.zhtml?c=122089&p=irol-newsArticle & ID=1298259&highlight=?